Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study - Report - MDSpire

Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study

  • By

  • Hamza Khan

  • Muhammad Saqib Khan

  • Sheraz Khan

  • Fang Liu

  • Quan Feng

  • Irfan Ahmad

  • Ge Tan

  • June 4, 2026

  • 0 min

Share

Clinical Report: Effectiveness of Rimegepant for Chronic and Episodic Migraine

Overview

This retrospective cohort study found that rimegepant significantly reduced migraine frequency and headache-related disability in patients with chronic and episodic migraine over a three-month period. All measured outcomes improved markedly, suggesting rimegepant's potential as an effective preventive therapy.

Background

Expand on the limitations of traditional therapies and their impact on patient adherence.

Data Highlights

Outcome MeasureBaselineMonth 3
Monthly Migraine Days (MMD)17.27 ± 8.522.90 ± 2.91
Monthly Headache Days (MHD)19.10 ± 7.465.60 ± 3.81
HIT-6 Score62.2745.47
MIDAS Score50.9912.44
MSQ Score59.9486.53

Key Findings

  • Rimegepant significantly reduced monthly migraine days from 17.27 to 2.90.
  • Monthly headache days decreased from 19.10 to 5.60.
  • HIT-6 scores improved from 62.27 to 45.47, indicating reduced headache impact.
  • MIDAS scores decreased from 50.99 to 12.44, reflecting lower headache-related disability.
  • MSQ scores increased from 59.94 to 86.53, suggesting improved quality of life.
  • Both chronic and episodic migraine patients showed significant improvements across all outcomes.

Clinical Implications

Rimegepant may serve as an effective preventive treatment option for patients with chronic and episodic migraine, particularly those who have not responded adequately to traditional therapies. Clinicians should consider its use in appropriate patients to enhance migraine management and improve quality of life.

Conclusion

The findings from this study support the use of rimegepant as a promising preventive therapy for migraine, warranting further investigation in prospective controlled trials to confirm its efficacy and safety.

Related Resources & Content

  1. Frontiers in Neurology, 2026 -- Systematic review and meta-analysis on the efficacy and safety of rimegepant for migraine
  2. Frontiers in Neurology, 2026 -- Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan
  3. Drug Safety, 2021 -- Safety and Tolerability of Fremanezumab for Migraine Prevention in Japanese Outpatients: Results from a Multicenter, Randomized, Open-Label Trial Over 12 Months
  4. Drugs - Real World Outcomes, 2023 -- Factors Influencing the Limited Effectiveness of Acute Migraine Treatments in Japan: Findings from the OVERCOME (Japan) Observational Study on Migraine Epidemiology, Treatment, and Care
  5. American College of Physicians, 2025 -- Prevention of Episodic Migraine Headache using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline
  6. PubMed, 2025 -- A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications
  7. Prevention of Episodic Migraine Headache using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline from the American College of Physicians
  8. A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications - PubMed

Original Source(s)

Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study

  • by Hamza Khan, Muhammad Saqib Khan, Sheraz Khan, Fang Liu, Quan Feng, Irfan Ahmad, Ge Tan

  • June 4, 2026

Related Content

Aripiprazole as second-line pharmacotherapy for a heterogeneous cohort of refractory functional dizziness disorders: a pilot preliminary retrospective study

CGRP Therapies May Reduce Migraine Days

Systematic review found high-certainty evidence for several calcitonin gene–related peptide–targeted therapies.

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models